文献速递肾小球疾病

激素、环孢素与霉酚酸酯多靶点治疗特发性膜性肾病:前瞻性随机对照试验

Multitarget therapy with a corticosteroid, cyclosporine and mycophenolate mofetil for idiopathic membranous nephropathy: a prospective randomized controlled trial.
PubMed 文献 · Nephrol Dial Transplant · 2023-01-01

本研究为单中心前瞻性随机对照试验,纳入78例特发性膜性肾病患者,比较泼尼松+环孢素+霉酚酸酯多靶点方案与6个月周期性激素-环磷酰胺方案的疗效与安全性。结论认为多靶点方案在诱导蛋白尿缓解方面非劣于激素-环磷酰胺周期性交替治疗,且安全性更好。

要点

  • 多靶点组12个月缓解率79%,激素-环磷酰胺组87%,组间无显著差异。
  • 多靶点组不良事件发生率46%,显著低于激素-环磷酰胺组的74%。
  • 多靶点方案在诱导蛋白尿缓解方面非劣于激素-环磷酰胺周期性交替治疗。

核心结论

  • 对于特发性膜性肾病患者,多靶点治疗在诱导蛋白尿缓解方面非劣于激素-环磷酰胺周期性交替治疗,且安全性优于激素-环磷酰胺联合方案。

研究设计与样本

  • 单中心、前瞻性、随机、对照试验,共纳入78例特发性膜性肾病患者,随机分为多靶点治疗组(泼尼松+环孢素+霉酚酸酯)和6个月周期性激素-环磷酰胺组,随访12个月。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The effectiveness of multitarget combination therapy with a corticosteroid, cyclosporine and mycophenolate mofetil for idiopathic membranous nephropathy (IMN) is unclear. In the present study, we aimed to compare the efficacy and safety of multitarget therapy with a cyclical corticosteroid-cyclophosphamide regimen in patients with IMN. METHODS: This was a single-centre, prospective, randomized, controlled trial. We randomly assigned patients with IMN to receive multitarget therapy (a combination of prednisone, cyclosporine and mycophenolate mofetil) or 6-month cyclical treatment with a corticosteroid and cyclophosphamide. The study patients were followed up for 12 months. The primary outcome was a composite of complete or partial remissions at 12 months. Adverse events were also assessed. RESULTS: The study cohort comprised 78 patients, 39 of whom received multitarget therapy and the other 39 cyclical alternating treatment with a corticosteroid and cyclophosphamide. At 12 months, 31 of 39 patients (79%) in the multitarget therapy group and 34 of 39 (87%) in the corticosteroid-cyclophosphamide group had achieved complete or partial remissions (relative risk 0.93; 95% confidence interval 0.72-1.21; P = .85; log-rank test). The prevalence of adverse events was significantly lower in the multitarget therapy group than in the corticosteroid-cyclophosphamide group [46% (18 of 39) vs 74% (29 of 39); P < .05]. CONCLUSIONS: Multitarget therapy for IMN patients is noninferior to cyclical alternating treatment with corticosteroid and cyclophosphamide in inducing proteinuria remission and has a better safety profile than the corticosteroid-cyclophosphamide combination.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Duan Y, Bai Y, Guo W, et al. Multitarget therapy with a corticosteroid, cyclosporine and mycophenolate mofetil for idiopathic membranous nephropathy: a prospective randomized controlled trial. Nephrol Dial Transplant. 2023. PMID: 37437905. doi:10.1093/ndt/gfad156

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。